News Headline Summary

Alexion (ALXN) says new data shows clinical benefits over 10 years of Soliris

- Says data shows Soliris significantly cuts Thromboembolism risk.

Reaction details (09:33)

- Co. shares spike 0.45% higher in immediate reaction to the news from USD 93.13 to USD 93.58.

10 Dec 2012 - 09:31 - Equities Data - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: